EPS for Omeros Corporation (OMER) Expected At $-0.34 as of May, 9

April 17, 2018 - By Elizabeth Jones

Omeros Corporation (NASDAQ:OMER) Corporate Logo
Big Money Sentiment decreased to 1.3 in 2017 Q4. It has change of 1.56, from 2017Q3’s 2.86. The ratio turned negative due to Omeros Corporation positioning: 14 sold and 29 reduced. 31 funds amassed holdings and 25 increased holdings. Investors holded 22.04 million in 2017Q3 but now own 21.94 million shares or 0.43% less.
Victory Cap Mngmt accumulated 1,570 shs. Blackrock owns 0% invested in Omeros Corporation (NASDAQ:OMER) for 3.93M shs. Adage Partners Gru Ltd holds 0.01% or 150,000 shs. 71,709 were accumulated by California State Teachers Retirement. Ftb Advisors accumulated 2,000 shs. Montana-based First Interstate Bancshares has invested 0.02% in Omeros Corporation (NASDAQ:OMER). Mcf Advsrs Ltd Liability has invested 0.01% in Omeros Corporation (NASDAQ:OMER). 105,909 were reported by Deutsche State Bank Ag. Raymond James & has 0% invested in Omeros Corporation (NASDAQ:OMER) for 36,840 shs. First Trust Advsrs Lp holds 0% in Omeros Corporation (NASDAQ:OMER) or 105,884 shs. Alliancebernstein Lp has invested 0% in Omeros Corporation (NASDAQ:OMER). Principal Financial Group Inc Inc owns 26,710 shs or 0% of their US capital. Washington Tru Retail Bank has 5,143 shs for 0.01% of their capital. Cambridge Rech Advsr Incorporated has invested 0% of its capital in Omeros Corporation (NASDAQ:OMER). C M Bidwell Assocs Limited has invested 0.09% in Omeros Corporation (NASDAQ:OMER).

Omeros Corporation registered $1.36 million net activity with 0 insider buys and 2 insider sales since January 3, 2018. 1,020 shs were sold by JACOBSEN MICHAEL A, worth $22,899 on Wednesday, January 3.

Omeros Corporation (NASDAQ:OMER) is awaited to announce earnings on May, 9., as reported by RTT. Analysts have expectation on stock’s EPS of $-0.34. That’s down 41.67 % from last year’s $-0.24 EPS. 36.00 % negative EPS growth is what Wall Street’s sees after $-0.25 reported EPS last quarter. Its shares touched $13.93 on during the last trading session after 1.76% change.Omeros Corporation has volume of 693,078 shares. Since April 17, 2017 OMER has declined 3.39% and is downtrending. OMER underperformed the S&P 500 by 14.94%.

Omeros Corporation (NASDAQ:OMER) Ratings Coverage

Total analysts of 6 have positions in Omeros (NASDAQ:OMER) as follows: 3 rated it a “Buy”, 0 with “Sell” and 3 with “Hold”. The positive are 50%. Since November 2, 2017 according to StockzIntelligence Inc Omeros has 14 analyst reports. The company rating was maintained by H.C. Wainwright on Thursday, December 14. On Wednesday, November 29 the rating was maintained by H.C. Wainwright with “Buy”. On Friday, March 2 Needham downgraded the shares of OMER in report to “Hold” rating. On Tuesday, November 28 the rating was maintained by Wedbush with “Buy”. In Friday, March 23 report H.C. Wainwright maintained the stock with “Buy” rating. On Thursday, November 2 the stock of Omeros Corporation (NASDAQ:OMER) earned “Market Perform” rating by Cowen & Co. On Thursday, January 4 the firm has “Buy” rating given by H.C. Wainwright. On Monday, March 26 the firm has “Buy” rating by WBB Securities given. On Friday, March 23 the rating was downgraded by Wedbush to “Neutral”. On Tuesday, January 23 the stock of Omeros Corporation (NASDAQ:OMER) has “Buy” rating given by H.C. Wainwright.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.The firm is worth $672.62 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement.Last it reported negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.

Omeros Corporation (NASDAQ:OMER) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.